Welcome to our dedicated page for Esperion Therape SEC filings (Ticker: ESPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Esperion Therapeutics, Inc. (ESPR) SEC filings page provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. Esperion is a commercial-stage biopharmaceutical company listed on the Nasdaq Stock Market LLC under the symbol ESPR, and its filings offer detailed insight into its cardiometabolic and rare/orphan disease business, including oral non-statin LDL-C therapies such as NEXLETOL and NEXLIZET.
Key filing types for Esperion include annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s business, risk factors, financial statements, and discussion of operations. Current reports on Form 8-K and 8-K/A, several of which are referenced in the provided data, disclose material events such as financial results, underwritten public offerings of common stock, executive appointments, board changes, and other significant corporate developments.
Investors can also review notifications of late filing on Form 12b-25, which explain delays in periodic reports and provide management’s narrative regarding the status of financial closing procedures. For Esperion, these documents have included explanations related to quarterly financial close and corrections to previously furnished earnings releases.
On Stock Titan, Esperion’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the content of lengthy documents, highlight key sections, and surface items such as revenue drivers, commercialization plans for NEXLETOL and NEXLIZET, capital-raising transactions, and changes in executive leadership. Users can also identify trading symbol information, exchange listing details, and other disclosures related to Esperion’s common stock directly from these filings.
Esperion Therapeutics agreed to be acquired by Essence Parent Inc., an affiliate of ARCHIMED. Under the merger agreement, shareholders will receive $3.16 in cash per share plus one contingent value right (CVR) per share, which can pay up to $100 million in cash in total if specified milestones are met.
The deal values Esperion’s equity at up to approximately $1.1 billion on a fully diluted basis and the cash price reflects a 58% premium to the April 30, 2026 closing share price. The transaction, unanimously approved by Esperion’s board, is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals and other customary conditions. Termination fees are set at $68,309,078 for Parent and $34,154,539 for Esperion in specified circumstances.
Esperion Therapeutics ownership disclosure: institutional investor Wasatch Advisors reports beneficial ownership of 15,768,897 shares of Common Stock, representing 6.1% of the class. The filing shows sole voting power of 12,377,523 shares and sole dispositive power of 15,768,897. The filing is signed by Mike Yeates, CEO, dated 04/22/2026.
Esperion Therapeutics is asking stockholders to vote at its virtual 2026 annual meeting on May 28, 2026. Stockholders will elect two Class I directors, approve on a non-binding basis the compensation of named executive officers, and ratify Ernst & Young LLP as auditor for 2026.
The company also seeks approval of an amendment to its 2022 Stock Option and Incentive Plan to increase the shares of common stock authorized for issuance under the plan by 7,000,000 shares, raising the plan’s share limit from 23,150,000 to 30,150,000. Esperion had 257,404,876 common shares outstanding as of March 31, 2026, each entitled to one vote.
The board states that equity awards are a key component of compensation, used to attract and retain employees and align their interests with stockholders. All directors (except the CEO) are deemed independent under Nasdaq rules, and the board maintains audit, compensation, nominating and governance, commercial, and compliance committees to oversee financial reporting, pay, board composition, commercial strategy, and regulatory compliance.
Esperion Therapeutics completed the acquisition of Corstasis Therapeutics, making Corstasis a wholly owned subsidiary and adding Enbumyst, an FDA‑approved bumetanide nasal spray for edema in cardiovascular, hepatic and renal disease. The company paid $75,000,000 in upfront cash, with Corstasis equityholders eligible for up to $180,000,000 in milestone payments plus future royalty and licensing‑revenue‑based payments.
To help fund the deal, Esperion amended its credit agreement to add $25,000,000 of new term loans and entered a Royalty Purchase Agreement, selling a portion of Otsuka‑related Bempedoic Acid royalties and milestones to Athyrium for $50,000,000. Athyrium will receive 100% of these specified receivables until it has collected $100,000,000, after which all such payments revert to Esperion.
The Vanguard Group filed Amendment No. 2 to a Schedule 13G/A reporting zero shares of Common Stock of Esperion Therapeutics Inc. as beneficially owned. The filing states 0 shares (0%) and lists zero voting and dispositive powers.
The filing includes a disclosure that certain Vanguard subsidiaries were disaggregated after an internal realignment effective January 12, 2026, and that those subsidiaries will report separately under SEC Release No. 34-39538.
Esperion Therapeutics, Inc. Chief Legal Officer Benjamin Looker reported an open-market sale of 5,708 shares of common stock. The shares were sold at an average price of $2.703 per share to satisfy tax obligations on vested restricted stock units. After this transaction, he directly holds 679,348 shares, indicating that the sale represents a small portion of his overall position.
Esperion Therapeutics’ President and CEO Sheldon L. Koenig reported an open-market sale of 25,578 shares of common stock at $2.719 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from vested restricted stock units.
After this transaction, Koenig directly holds 2,172,699 shares of Esperion Therapeutics common stock. This filing reflects a tax-related disposition rather than a discretionary reduction of his overall shareholding.
Esperion Therapeutics Chief Financial Officer Benjamin Halladay reported an open-market sale of 6,424 shares of common stock at $2.705 per share. According to the footnote, the shares were sold to satisfy tax obligations on vested restricted stock units. After this tax-related sale, he directly holds 713,602 shares.
ESPR filed a Form 144 reporting a proposed sale of 6,424 shares of Common Stock tied to restricted stock vesting on 03/16/2026. The filing also lists a prior sale of 7,337 shares on 12/17/2025 for 26906.25.